Cinqair, Cinqaero(reslizumab)
Cinqaero, Cinqair (reslizumab) is an antibody pharmaceutical. Reslizumab was first approved as Cinqair on 2016-03-23. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Cinqair
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cinqair | Biologic Licensing Application | 2020-06-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2786 | Injection, reslizumab, 1 mg |
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 3 | 4 | 1 | — | 7 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary eosinophilia | D011657 | EFO_0007257 | J82.81 | — | 1 | 7 | — | — | 7 |
| Eosinophilia | D004802 | — | D72.1 | — | — | 5 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Churg-strauss syndrome | D015267 | EFO_0007208 | M30.1 | — | 1 | — | — | — | 1 |
| Granulomatosis with polyangiitis | D014890 | EFO_0005297 | M31.3 | — | 1 | — | — | — | 1 |
| Systemic vasculitis | D056647 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Reslizumab |
| INN | reslizumab |
| Description | Reslizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107884 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06602 |
| UNII ID | 35A26E427H (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,451 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cinqair
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
614 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use